Dendreon Corporation
Seattle, WA, US· latest recorded location
Dendreon Corporation is named on 53 US grants and 37 published applications in this corpus. Its most frequent classification is A61P (Therapeutic uses of medicines).
- Granted patents
- 53
- Published applications
- 37
- Inventors
- 92
- Granted in 2026 so far
- 0
- Most recent grant
- 16 Apr 2019
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 2 |
| 2003 | 0 | 4 |
| 2004 | 2 | 5 |
| 2005 | 1 | 4 |
| 2006 | 7 | 2 |
| 2007 | 6 | 2 |
| 2008 | 3 | 4 |
| 2009 | 4 | 1 |
| 2010 | 4 | 2 |
| 2011 | 2 | 2 |
| 2012 | 3 | 5 |
| 2013 | 7 | 2 |
| 2014 | 2 | 0 |
| 2015 | 1 | 2 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 0 |
By publication year.
Technology areas
Share of 90 documents
- A61PTherapeutic uses of medicines68
- A61KMedicines and medical preparations66
- C07KPeptides52
- C12NMicroorganisms or enzymes25
- G01NInvestigating or analysing materials by determining their chemical or physical properties19
- C07CAcyclic or carbocyclic compounds18
- C07DHeterocyclic compounds18
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests8
- C12YEnzymes4
- B01LChemical or physical laboratory apparatus for general use2
Recent patents
- Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome16 Apr 2019US 10,261,091 B2
- Compositions employing alternative reading frame polypeptides for the treatment of cancer and infectious disease9 Jun 2015US 9,051,385 B2
- Promiscuous HER-2/Neu CD4 T cell epitopes25 Feb 2014US 8,658,177 B2
- Promiscuous PAP CD4 T cell epitopes11 Feb 2014US 8,647,865 B2
- Small-molecule modulators of Trp-p8 activity31 Dec 2013US 8,618,155 B2
- Compositions and methods for the treatment of disease associated with trp-p8 expression24 Sep 2015US 2015/0266810 A1
- Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome5 Mar 2015US 2015/0064210 A1
- Promiscuous pap cd4 t cell epitopes8 Aug 2013US 2013/0203163 A1
- Compositions and methods for the treatment of disease associated with trp-p8 expression25 Jul 2013US 2013/0190296 A1
- Promiscuous her-2/neu cd4 t cell epitopes6 Dec 2012US 2012/0308513 A1
Most cited
By later US patents
- Peptides as NS3-serine protease inhibitors of hepatitis C virus84US 7,012,066 B22006
- Immunostimulatory method77US 6,080,409 A2000
- Peptides as NS3-serine protease inhibitors of hepatitis C virus51US 7,244,721 B22007
- Peptides as NS3-serine protease inhibitors of hepatitis C virus47US 6,800,434 B22004
- Selective apoptosis of neoplastic cells by an HLA-DR specific monoclonal antibody44US 6,416,958 B22002